When was Precigen founded?

Precigen was founded in 1998 and raised its 1st funding round 13 years after it was founded.

Where is Precigen located?

Precigen is headquartered in Germantown, United States.

How many employees does Precigen have?

As of Sep 30, 2026, the latest employee count at Precigen is 158.

Is Precigen a funded company?

Precigen is a funded company, having raised a total of $234M across 4 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Apr 22, 2011.

When was the latest funding round of Precigen?

Precigen's latest funding was a $***** Post IPO round on Dec 17, 2020, with participation from 0 investor.

What is the annual revenue of Precigen?

Annual revenue of Precigen is between $1M and $10M as on Dec 31, 2025

Where does Precigen rank among its competitors?

Precigen ranks 24th amongst 704 active competitors, of which 258 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Precigen?

Precigen's top competitors include BeiGene, Biogen and argenx. Among them, Immuneel secured the most recent funding round in June, 2026.

Precigen - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases. It advances gene and cell therapies using precision technology. The company operates as an innovation engine, progressing a preclinical and clinical pipeline of differentiated therapies toward clinical proof-of-concept and commercialization. It utilizes non-viral and viral expression systems, genome, DNA, RNA and protein engineering, and precision bioengineering switch technologies to deliver on-target gene and cell therapies.

Website: precigen.com
Social
Email ID: *****@precigen.com
Phone Number: +1 **********

Key Metrics

Founded Year

1998

Location

Germantown, United States

Stage

Public

Total Funding

$234M in 4 rounds

Latest Funding Round

Post IPO, Dec 17, 2020, $*****

Investors

Checkmate Capital

Ranked

24^th among 704 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

158 as on Sep 30, 2026

Investment & Acquisitions

Genvec & 10 more

Similar Companies

BeiGene & 816 more

Exit Details

Public

View Precigen's full profile

Precigen is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
INTREXON CORP CIN: 1356090 , United States, Active		$100M - $500M (As on Dec 31, 2018)	-	-
Precigen, Inc. CIN: 5238736 , United States, Active	Nov 21, 2017	-	-	-
Precigen, Inc. CIN: 1356090 , United States, Active		$1M - $10M (As on Dec 31, 2025)	25 (As on Dec 31, 2023)	-

Precigen got listed on Aug 08, 2013.

Click here to take a look at Precigen's IPO in detail

Precigen has raised a total funding of $234M over 4 rounds. Its first funding round was on Apr 22, 2011. Precigen has 1 institutional investor.

Here is the list of recent funding rounds of Precigen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 17, 2020	1631876	Post IPO	9002859	3908784	8477662	4500266
Apr 25, 2012	6474798	Series D	5553516	5521433	2261222	1584268
Jun 07, 2011	8675422	Series D	5104536	8051001	3546312	6032493

Access funding benchmarks and valuations. Sign up today!

View details of Precigen's funding rounds and investors

The founders of Precigen is Thomas David Reed.

Here are the details of Precigen's key team members:

Thomas David Reed: Founder of Precigen.
Contact Info: 1 email address

View details of Precigen's Founder profiles and Board Members

Precigen's employee count trend

Precigen has 158 employees as of Sep 26. Here is Precigen's employee count trend over the years:

Uncover Precigen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Precigen include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Precigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
7th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
9th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
10th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
24th	Precigen 1998, Germantown (United States), Public	Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases	$234M	Checkmate Capital	64/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Precigen's competitors? Click here to see the top ones

Precigen has made 3 investments in companies including AquaBounty and Oragenics. Precigen has also acquired 8 companies including Genvec and Oxitec.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 24, 2017	Acquisition	Genvec	1992	Gaithersburg (United States)
Feb 24, 2016	Investments	AquaBounty	1991	Harvard (United States)
Aug 10, 2015	Acquisition	Oxitec	2002	Abingdon (United Kingdom)